By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating in Shanghai, People's Republic of China, by NewsRx journalists, research stated, "Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of the thyroid-specific expression of the human sodium iodide symporter (hNIS). Here, we explore the efficacy of a novel form of gene therapy using prostate-specific membrane antigen (PSMA) promoter-mediated hNIS gene transfer followed by radioiodine administration for the treatment of castration-resistant prostate cancer (CRPC)."
The news reporters obtained a quote from the research from Changhai Hospital, "The androgen-dependent C33 LNCaP cell line and the androgen-independent C81 LNCaP cell line were transfected by adenovirus. PSMA promoter-hNIS (Ad.PSMApro-hNIS) or adenovirus.cytomegalovirus-hNIS containing the cytomegalovirus promoter (Ad.CMV-hNIS) or a control virus. The iodide uptake was measured in vitro. The in vivo iodide uptake by C81 cell xenografts in nude mice injected with an adenovirus carrying the hNIS gene linked to PSMA and the corresponding tumor volume fluctuation were assessed. Iodide accumulation was shown in different LNCaP cell lines after Ad.PSMApro-hNIS and Ad.CMV-hNIS infection, but not in different LNCaP cell lines after adenovirus.cytomegalovirus (Ad.CMV) infection. At each time point, higher iodide uptake was shown in the C81 cells infected with Ad.PSMApro-hNIS than in the C33 cells (P < 0.05). An in vivo animal model showed a significant difference in (131) I radioiodine uptake in the tumors infected with Ad.PSMApro-hNIS, Ad.CMV-hNIS and control virus (P < 0.05) and a maximum reduction of tumor volume in mice infected with Ad.PSMApro-hNIS."
According to the news reporters, the research concluded: "These results show prostate-specific expression of the hNIS gene delivered by the PSMA promoter and effective radioiodine therapy of CRPC by the PSMA promoter-driven hNIS transfection."
For more information on this research see: Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter. Asian Journal of Andrology, 2014;16(1):120-123. Asian Journal of Andrology can be contacted at: Medknow Publications & Media Pvt Ltd, B-9, Kanara Business Centre, Off Link Rd, Ghaktopar-E, Mumbai, 400075, India. (Nature Publishing Group - www.nature.com/; Asian Journal of Andrology - www.nature.com/aja/)
Our news correspondents report that additional information may be obtained by contacting X.F. Gao, Second Military Med Univ, Changhai Hosp, Dept. of Urol, Shanghai 200433, People's Republic of China. Additional authors for this research include T. Zhou, G.H. Chen, C.L. Xu, Y.L. Ding and Y.H. Sun (see also Biotechnology).
Keywords for this news article include: CMV, Asia, Biotechnology, Viral, Shanghai, Hormones, Oncology, Virology, Chemicals, Chemistry, DNA Viruses, Radiotherapy, Sodium Iodide, Bioengineering, Prostate Cancer, Sodium Compounds, Betaherpesvirinae, Cancer Gene Therapy, Prostatic Neoplasms, DNA Virus Infections, Herpesviridae Infections, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC